Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Obesity
FollowWhat is new in Obesity research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Abrupt cessation of semaglutidePhase 3 · NCT07294950
- AleniglipronPhase 3 · NCT07654361 · NCT07654374
- ALN-CIDEBPhase 3 · NCT07854782
- ASC30 tablets A1Phase 3 · NCT07743463 · NCT07743450
- AutoinjectorPhase 3 · NCT07871409
- BerobenatidePhase 3 · NCT07881757 · NCT07874633 · NCT07792954 · NCT07876531 · NCT07845500 · NCT07794761 · NCT07794774 · NCT07823608 · NCT07915609
- BGM0504Phase 3 · NCT07743983
- BIC/FTC/TAFPhase 3 · NCT07075146
- BofanglutidaPhase 3 · NCT07622810
- Bupropion 150 mgPhase 3 · NCT07806279
- CagrilintidePhase 3 · NCT07557953 · NCT05567796 · NCT06780449 · NCT07253285 · NCT07010432 · NCT07607587 · NCT07745504 · NCT07220642 · NCT07220759 · NCT07411560 · NCT07527195
- CagrisemaPhase 3 · NCT07564414
- CagriSema (Cagrilintide B and Semaglutide I)Phase 3 · NCT07011667
- DA-302168SPhase 3 · NCT07877038 · NCT07629544
- Daily dose of cholecalciferol per osPhase 3 · NCT03516968
- DOR/3TC/TDFPhase 3 · NCT07075146
- Ecnoglutide InjectionPhase 3 · NCT07836270 · NCT07734311
- ElecoglipronPhase 3 · NCT07667803 · NCT07775404 · NCT07534592
- EloralintidePhase 3 · NCT07765511 · NCT07282600 · NCT07665879 · NCT07738614 · NCT07589608 · NCT07900633 · NCT07353931 · NCT07215559 · NCT07808060 · NCT07392190 · NCT07321886 · NCT07881432 · NCT07369011
- eloralintide and tirzepatidePhase 3 · NCT07881458 · NCT07881432
- EnicepatidePhase 3 · NCT07589686 · NCT07351045 · NCT07351058 · NCT07670416
- Exenatide 2 mg [Bydureon]Phase 3 · NCT04520490
- FoodRxPhase 3 · NCT05309395
- Gradual dose reduction of semaglutidePhase 3 · NCT07294950
- GZR18Phase 3 · NCT06728124 · NCT07150975
- GZR18 injectionPhase 3 · NCT07493057 · NCT07144098 · NCT07292441 · NCT07141030
- HDM1002 200mg, oral, once daily, 52 weeksPhase 3 · NCT06885021
- HDM1002 400mg, oral, once daily, 52 weeksPhase 3 · NCT06885021
- HDM1002 placebo, oral, once daily, 52 weeksPhase 3 · NCT06885021
- HDM1005Phase 3 · NCT07794397 · NCT07828197 · NCT07559240 · NCT07787260
- HDM1005 1Phase 3 · NCT07279194
- HDM1005 2Phase 3 · NCT07279194
- HDM1702Phase 3 · NCT07036172
- HRS-7535Phase 3 · NCT07528027
- HRS9531Phase 3 · NCT06994650 · NCT06974851
- HRS9531 injectionPhase 3 · NCT07285902
- HRS9531 TabletPhase 3 · NCT07670884
- HRS9531 Tablet PlaceboPhase 3 · NCT07670884
- HRS9531placeboPhase 3 · NCT06974851
- IBI362Phase 3 · NCT06862908 · NCT07469800 · NCT06884293 · NCT06931028 · NCT07255209 · NCT07000955
- IN-B00009Phase 3 · NCT07192263
- LenbelintidePhase 3 · NCT07784270 · NCT07776509 · NCT07784725
- LevothyroxinePhase 3 · NCT07332273
- LiraglutidePhase 3 · NCT04775082 · NCT07225816
- Maridebart cafraglutidePhase 3 · NCT07225686 · NCT07866066 · NCT07037433 · NCT07871409 · NCT07441252 · NCT06858839 · NCT07684235 · NCT07832799 · NCT07523711 · NCT07908316 · NCT06987695 · NCT07226765 · NCT06660173 · NCT07037459 · NCT07684144 · NCT07575399 · NCT06858878
- MDR-001Phase 3 · NCT07110766 · NCT07274137
- Mesh repairPhase 3 · NCT05488288
- MET097Phase 3 · NCT07311850 · NCT06973720
- MetfominPhase 3 · NCT07622290 · NCT07395960
- MetforminPhase 3 · NCT07331389 · NCT05414409 · NCT07065591 · NCT07297290 · NCT07502001 · NCT06446531
- Metformin 850 mg oral tablet bidPhase 3 · NCT04578652
- MibavademabPhase 3 · NCT07220772
- MirikizumabPhase 3 · NCT06937099 · NCT06937086
- Monthly bolus of cholecalciferol per osPhase 3 · NCT03516968
- MWN109 1Phase 3 · NCT07791537 · NCT07804797 · NCT07778693
- MWN109 2Phase 3 · NCT07791537 · NCT07804797 · NCT07778693
- MWN109 3Phase 3 · NCT07791537 · NCT07778693
- NNC0487-0111Phase 3 · NCT07571005 · NCT07503210 · NCT07481630 · NCT07400107 · NCT07508020 · NCT07533175 · NCT07567001 · NCT07757087 · NCT07339423 · NCT07587710 · NCT07822061 · NCT07509307 · NCT07571109
- OlatorepatidePhase 3 · NCT07685808 · NCT07896265 · NCT07431086 · NCT07830329
- OrforglipronPhase 3 · NCT06672939 · NCT06672549 · NCT07793019 · NCT06972472 · NCT07153471 · NCT07790861 · NCT07794579 · NCT05869903 · NCT06993792 · NCT06948435 · NCT07202884 · NCT06948422 · NCT06972459 · NCT06952530
- PetrelintidePhase 3 · NCT07843472 · NCT07843485 · NCT07589686 · NCT07843498
- PF-08653944Phase 3 · NCT07575932 · NCT07400653 · NCT07595549 · NCT07508241 · NCT07845513
- Qsymia 7.5 miligrams (mg)-46 mg Extended Release CapsulePhase 3 · NCT06905626
- RAY1225Phase 3 · NCT07362030 · NCT06254261 · NCT06893016
- RetatrutidePhase 3 · NCT06383390 · NCT06662383 · NCT06859268 · NCT07232719 · NCT07357415 · NCT07035093
- RibupatidePhase 3 · NCT07284875 · NCT07284979 · NCT07284901 · NCT07793929 · NCT07458269
- Ribupatide InjectionPhase 3 · NCT07709910
- SemaglutidePhase 3 · NCT07866066 · NCT05726227 · NCT07668414 · NCT05567796 · NCT07855133 · NCT06780449 · NCT07253285 · NCT07743983 · NCT06884293 · NCT07639021 · NCT07812597 · NCT06299098 · NCT07101939 · NCT07400107 · NCT07411378 · NCT07010432 · NCT06499857 · NCT05173714 · NCT07845500 · NCT06937060 · NCT07225816 · NCT06745284 · NCT07845578 · NCT07622810 · NCT07564414 · NCT07505303 · NCT06717698 · NCT07284979 · NCT07466017 · NCT05202353 · NCT06005012 · NCT07891156 · NCT07767175 · NCT07527195 · NCT07770841
- Semaglutide (Wegovy) weekly injectionPhase 3 · NCT07446998 · NCT07845994 · NCT07820358 · NCT07430059
- Semaglutide 1.7mg subcutaneousPhase 3 · NCT07021937
- Semaglutide 2.4 mgPhase 3 · NCT06934655
- Semaglutide 2.4mgPhase 3 · NCT06909006 · NCT06173778
- Semaglutide InjectionPhase 3 · NCT07465965 · NCT07285902 · NCT07073417 · NCT06577090
- Semaglutide placeboPhase 3 · NCT06909006 · NCT07639021
- Semaglutide(Wegovy® )Phase 3 · NCT07150975
- SetmelanotidePhase 3 · NCT06760546 · NCT06772597 · NCT07496463 · NCT05774756
- SufentanilPhase 3 · NCT07844512
- SurvodutidePhase 3 · NCT07850063 · NCT07855900 · NCT06745284 · NCT07850050
- Suture repairPhase 3 · NCT05488288
- Tegileridine (tegileridine fumarate injection, IV)Phase 3 · NCT07844512
- TirzepatidePhase 3 · NCT06517212 · NCT07298915 · NCT05822544 · NCT07846865 · NCT06847399 · NCT06700538 · NCT06180616 · NCT06811324 · NCT07078838 · NCT06802081 · NCT06582875 · NCT05556512 · NCT07829198 · NCT07481747 · NCT07245771 · NCT06962280 · NCT07179120 · NCT07095517 · NCT07817875 · NCT06759701 · NCT07521631 · NCT06439277 · NCT05912621 · NCT06934642 · NCT07868354 · NCT06662383 · NCT06037252 · NCT06937099 · NCT07874828 · NCT07803744 · NCT07842640 · NCT07845500 · NCT07299084 · NCT06965413 · NCT07292519 · NCT07065552 · NCT07228741 · NCT06162715 · NCT06994338 · NCT07000955 · NCT06937086 · NCT07747805 · NCT07881458 · NCT06643728 · NCT06732245 · NCT07284511 · NCT07738276 · NCT07693608 · NCT06565611 · NCT07463846 · NCT07881432 · NCT05933499 · NCT06143956 · NCT06914895 · NCT07349641 · NCT06075667 · NCT06918405 · NCT06751589
- TradipitantPhase 3 · NCT07446439
- UBT251Phase 3 · NCT07785934 · NCT07134335 · NCT07767942 · NCT07395687 · NCT07710768 · NCT07710729 · NCT07806851
- UBT251 Injection 4.0 mgPhase 3 · NCT07648225
- UBT251 Injection 6.0 mgPhase 3 · NCT07648225
- UBT251 Injection Placebo 4.0 mgPhase 3 · NCT07648225
- UBT251 Injection Placebo 6.0 mgPhase 3 · NCT07648225
- VibegronPhase 3 · NCT06987383
- VK2735Phase 3 · NCT07868835 · NCT07104500 · NCT07104383
- VK2735 OralPhase 3 · NCT07868939
- Wegovy ®Phase 3 · NCT07036172 · NCT06830343
- XW003 injectionPhase 3 · NCT07434050 · NCT07387094 · NCT07073417
- ZenagamtidePhase 3 · NCT07668401 · NCT07668414 · NCT07855133 · NCT07861100 · NCT07868354 · NCT07720271
- Zovaglutide dose 1Phase 3 · NCT07230119
- Zovaglutide dose 2Phase 3 · NCT07230119
- Abdominal adipose tissue biopsyPhase 2/3 · NCT05653258
- Continuous Positive Airway PressurePhase 2/3 · NCT07846865
- Dasatinib 100 MGPhase 2/3 · NCT05653258
- EmpagliflozinPhase 2/3 · NCT07331389 · NCT06745063 · NCT06149793
- GnRH antagonistPhase 2/3 · NCT06390904 · NCT06379113
- Letrozole 2.5mgPhase 2/3 · NCT06390904 · NCT06379113
- Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 MgPhase 2/3 · NCT05316493
- Megestrol Acetate 160 MG Oral TabletPhase 2/3 · NCT05316493
- Phase IIb：Efsubaglutide Alfa 10 mg QWPhase 2/3 · NCT06921486
- Phase IIb：Efsubaglutide Alfa 20 mg Q2WPhase 2/3 · NCT06921486
- Phase IIb：Efsubaglutide Alfa 20 mg QWPhase 2/3 · NCT06921486
- Phase IIb：Efsubaglutide Alfa 5 mg QWPhase 2/3 · NCT06921486
- Phase IIb：PlaceboPhase 2/3 · NCT06921486
- Phase III：PlaceboPhase 2/3 · NCT06921486
- Phase III：Recommended Phase 3 Dose High DosePhase 2/3 · NCT06921486
- Phase III：Recommended Phase 3 Dose Low DosePhase 2/3 · NCT06921486
- PhotobiomodulationPhase 2/3 · NCT05816798
- Photobiomodulation PlaceboPhase 2/3 · NCT05816798
- Quercetin 1000mgPhase 2/3 · NCT05653258
- Sacubitril-Valsartan 49 Mg-51 Mg Oral TabletPhase 2/3 · NCT04971720
- Semaglutide Injectable ProductPhase 2/3 · NCT06423599
- Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM)Phase 2/3 · NCT07284511
- Valsartan 80 mg Oral TabletPhase 2/3 · NCT04971720
- (S)-pindolol benzoatePhase 2 · NCT07101939
- ABBV-295Phase 2 · NCT07752979 · NCT07514260 · NCT07291232
- AKKPhase 2 · NCT07593170
- AlirocumabPhase 2 · NCT07477704
- Alli® 60 mgPhase 2 · NCT06993428
- Alpha-lipoic acidPhase 2 · NCT05713799
- ALV-100Phase 2 · NCT07837973 · NCT07399678
- APHD-002Phase 2 · NCT07008456
- APHD-012Phase 2 · NCT07008456
- APHP-002Phase 2 · NCT07008456
- APHP-012Phase 2 · NCT07008456
- AT673 high dosePhase 2 · NCT07724340
- AT673 low dosePhase 2 · NCT07724340
- AtomoxetinePhase 2 · NCT06899178
- ATR-258Phase 2 · NCT07421024
- AZD6234Phase 2 · NCT07017179 · NCT07013643
- AZD6234 in combination with AZD9550Phase 2 · NCT07017179
- AZD9550Phase 2 · NCT07017179 · NCT06151964 · NCT07013643
- AzithromycinPhase 2 · NCT06488781
- BGM0504 placeboPhase 2 · NCT07658560
- BGM0504 tabletsPhase 2 · NCT07658560
- BI 3034701Phase 2 · NCT07693231 · NCT07754474 · NCT07662122
- BimagrumabPhase 2 · NCT06643728 · NCT05933499
- Bimagrumab PlaceboPhase 2 · NCT06643728
- BIO101Phase 2 · NCT07411378
- BiopsyPhase 2 · NCT04931017
- Biospecimen CollectionPhase 2 · NCT04931017
- bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester)Phase 2 · NCT07097506
- BivamelagonPhase 2 · NCT07156578
- bremelanotidePhase 2 · NCT06565611
- BronchoscopyPhase 2 · NCT04931017
- CannabisPhase 2 · NCT06137365
- CelecoxibPhase 2 · NCT07139405
- ClazakizumabPhase 2 · NCT07783802
- CS060380Phase 2 · NCT07466017
- CXA-10Phase 2 · NCT03762395
- DapiglutidePhase 2 · NCT05788601
- DextrinPhase 2 · NCT06827002 · NCT07884058
- Disulfiram (DSF)Phase 2 · NCT07534332
- Dose escalation to 2 mg semaglutide weekly then no semaglutidePhase 2 · NCT07325500
- Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weeklyPhase 2 · NCT07325500
- ECC4703Phase 2 · NCT07505303
- Efsubaglutide Alfa 20 mg QWPhase 2 · NCT07114419 · NCT07693426
- Efsubaglutide Alfa 40 mg Q2WPhase 2 · NCT07114419
- Efsubaglutide Alfa 40 mg QWPhase 2 · NCT07114419
- Efsubaglutide Alfa 80 mg Q4WPhase 2 · NCT07114419
- Efsubaglutide Alfa 80 mg QWPhase 2 · NCT07114419
- Eloralintide PlaceboPhase 2 · NCT07215559
- EMP16-02 120 mg orlistat/40 mg acarbosePhase 2 · NCT06993428
- Empagliflozin (oral)Phase 2 · NCT07336797
- Enicepatide-matching PlaceboPhase 2 · NCT07589686
- EnobosarmPhase 2 · NCT07446998
- ERX1000Phase 2 · NCT07570758
- Esophageal pressure-guided PEEP titrationPhase 2 · NCT07359261
- Estradiol PatchesPhase 2 · NCT06686537
- Extended Release Metformin HydrochloridePhase 2 · NCT04931017
- FIM intervention armPhase 2 · NCT07332741
- FIM Usual Care ArmPhase 2 · NCT07332741
- GaretosmabPhase 2 · NCT06299098
- Gastric fundal mucosal ablation (GFMA), Bariatric endoscopic antral myotomy (BEAM)Phase 2 · NCT07612527
- GL0034 Dose Level 1Phase 2 · NCT07282743
- GL0034 Dose Level 2Phase 2 · NCT07282743
- GL0034 Dose Level 3Phase 2 · NCT07282743
- GL0034 Dose Level 4Phase 2 · NCT07282743
- GL0034 Dose Level 5Phase 2 · NCT07282743
- GL0034 Dose Level 6Phase 2 · NCT07282743
- GLP-1 receptor agonistPhase 2 · NCT07314528 · NCT06903923
- gut-brain axis (GLP-1)-activating food carbohydratePhase 2 · NCT07823452
- HDM1005 dose level 1Phase 2 · NCT07521631
- HDM1005 dose level 2Phase 2 · NCT07521631
- HDM1005 dose level 3Phase 2 · NCT07521631
- HDM1005 injection or placeboPhase 2 · NCT06886126
- HM15275Phase 2 · NCT07205900
- HRS-4729 InjectionPhase 2 · NCT07690826
- HRS-4729 Injection PlaceboPhase 2 · NCT07690826
- HRS-4729 Injection;Phase 2 · NCT07690826
- HRS-7535 tabletPhase 2 · NCT06820099
- HRS-7535 tablet placeboPhase 2 · NCT06820099
- IGOB131Phase 2 · NCT07884058
- IMM01-STEMPhase 2 · NCT06600581
- IMM01-STEM alternating with placebo (saline)Phase 2 · NCT06600581
- Intranasal Oxytocin 40 i.u.Phase 2 · NCT07902752
- Intranasal Placebo SprayPhase 2 · NCT07902752
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120Phase 2 · NCT07882654
- KAI-7535Phase 2 · NCT07497880
- KBP-336Phase 2 · NCT06833749
- KDS2010Phase 2 · NCT07009171
- L-ctirullinePhase 2 · NCT03885245
- LAE102 +TirzepatidePhase 2 · NCT07671391
- LAE102 placebo,+TirzepatidePhase 2 · NCT07671391
- Levonorgestrel-releasing intrauterine systemPhase 2 · NCT07781150
- Levonorgestrel-releasing IUD.Phase 2 · NCT05903131
- Lisdexamfetamine DimesylatePhase 2 · NCT06847399
- LNG-IUD (Progestin)Phase 2 · NCT07820358
- LUM-201Phase 2 · NCT07754045
- LY3305677Phase 2 · NCT06143956
- LY3457263Phase 2 · NCT06897475
- LY3532226Phase 2 · NCT06143956
- LY3549492Phase 2 · NCT06143956
- LY3841136Phase 2 · NCT06143956
- LY4086940Phase 2 · NCT07890376
- MacupatidePhase 2 · NCT07765511 · NCT07589608 · NCT07215559
- Macupatide PlaceboPhase 2 · NCT07215559
- Matching PlaceboPhase 2 · NCT03762395 · NCT07793019 · NCT07479862 · NCT03885245 · NCT07846033
- Matching Placebo-GaretosmabPhase 2 · NCT06299098
- Matching Placebo-Part APhase 2 · NCT06299098
- Matching Placebo-TrevogrumabPhase 2 · NCT06299098
- Mazdutide(Dual GLP-1R/GCGR Agonist)Phase 2 · NCT07781150
- Metformin hydrochloride extended-release tabletsPhase 2 · NCT06273072
- Metformin XRPhase 2 · NCT07139405
- Midazolam (sedative)Phase 2 · NCT06835101
- MirabegronPhase 2 · NCT05713799
- MKP10241Phase 2 · NCT07098663
- MOTS-c (MDP)Phase 2 · NCT07505745
- NA-931Phase 2 · NCT06732245
- NA-931 150 mg + no TirzepatidePhase 2 · NCT06732245
- NicotinamidePhase 2 · NCT06599918
- Nicotine Replacement Therapy (NRT, nicotine patch)Phase 2 · NCT06173778
- Nimacimab 300 mg injectionPhase 2 · NCT06577090
- Nimacimab injectionPhase 2 · NCT06577090
- Nimacimab placebo injectionPhase 2 · NCT06577090
- NNC0519-0130Phase 2 · NCT06717698
- NNC0662-0419Phase 2 · NCT07639021 · NCT07525791 · NCT07184632
- NNC0662-0419 PlaceboPhase 2 · NCT07639021
- Oral BGE-102Phase 2 · NCT07656727
- Oral Placebo Matching BGE-102Phase 2 · NCT07656727
- Oxytocin nasal sprayPhase 2 · NCT04551482
- Petrelintide-matching PlaceboPhase 2 · NCT07589686
- PF-08653945Phase 2 · NCT07575932 · NCT07725809
- PG-102Phase 2 · NCT06891287 · NCT06712615
- PhenterminePhase 2 · NCT07282340
- Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]Phase 2 · NCT06299891
- Phentermine-TopiramatePhase 2 · NCT04721873
- Phentermine/Topiramate ERPhase 2 · NCT07790913
- PloceboPhase 2 · NCT07017179
- ProgestinPhase 2 · NCT05903131
- PuerarinPhase 2 · NCT06968208
- Retatrutide (LY3437943)Phase 2 · NCT07467447
- RO7204239Phase 2 · NCT07137585 · NCT06965413
- RO7204239 Matching PlaceboPhase 2 · NCT06965413
- S1B-509 High DosePhase 2 · NCT06517797
- S1B-509 low dosePhase 2 · NCT06517797
- SemagludtidePhase 2 · NCT07754045
- Semaglutide (administered by PDS290 pen-injector)Phase 2 · NCT07731256
- Semaglutide (Rybelsus®)Phase 2 · NCT07179120 · NCT06827002 · NCT07642635
- Semaglutide (Wegovy®)Phase 2 · NCT07909889
- Semaglutide Pen InjectorPhase 2 · NCT05746039 · NCT05067621 · NCT06411210
- Semaglutide Pen Injector 2.4mg weeklyPhase 2 · NCT05254314
- SYH2069 InjectionPhase 2 · NCT07803991 · NCT07736391
- SYH2069 Injection PlaceboPhase 2 · NCT07803991
- Taldefgrobep AlfaPhase 2 · NCT07281495
- TE-8105 MAD Cohort 1Phase 2 · NCT07857473
- TE-8105 MAD Cohort 2Phase 2 · NCT07857473
- TE-8105 MAD Cohort 3Phase 2 · NCT07857473
- TesamorelinPhase 2 · NCT06554717
- THDBH120 injectionPhase 2 · NCT07036601
- Tirzepatide PlaceboPhase 2 · NCT06643728
- Total neoadjuvant therapy (TNT)Phase 2 · NCT07314528
- Transcranial Direct Current Stimulation (TDCS)Phase 2 · NCT00739362
- Trevogrumab-Part APhase 2 · NCT06299098
- Trevogrumab-Part B and Part CPhase 2 · NCT06299098
- ValsartanPhase 2 · NCT07139405 · NCT07331389
- VCT220 Placebo TabletPhase 2 · NCT07360275
- VCT220 TabletPhase 2 · NCT07360275
- Vericiguat 10 MGPhase 2 · NCT06320951
- Visually identical placebo Metformin hydrochloride extended-release tabletsPhase 2 · NCT06273072
- zovaglutide Arm 1Phase 2 · NCT07812597
- zovaglutide Arm 2Phase 2 · NCT07812597
- ZT006Phase 2 · NCT07230132
- A fiixed combination of Chinese herbal medicinePhase 1/2 · NCT06703788
- ACCG-2671Phase 1/2 · NCT07815678
- ALN-2232Phase 1/2 · NCT07463846
- ALN-4324Phase 1/2 · NCT06845202
- Aminohippurate Sodium Inj 20%Phase 1/2 · NCT03584217
- AmlodipinePhase 1/2 · NCT05312892
- ARO-ALK7Phase 1/2 · NCT06937203
- ARO-INHBEPhase 1/2 · NCT06700538
- Ascorbic acid solution (American Regent Laboratories Inc.)Phase 1/2 · NCT04715022
- AZD9550 and AZD6234Phase 1/2 · NCT06151964
- BS groupPhase 1/2 · NCT07336862
- BS-GLP groupPhase 1/2 · NCT07336862
- Bupropion Hydrochloride Extended-releasePhase 1/2 · NCT07398404
- Cissus quadrangulariaPhase 1/2 · NCT06827002
- DeltaGold® Tocotrienol 70%Phase 1/2 · NCT03705845
- Dichrostachys glomerataPhase 1/2 · NCT06827002
- DrospirenonePhase 1/2 · NCT06345560
- ecnoglutide tabletsPhase 1/2 · NCT07243171
- Empagliflozin 25 MGPhase 1/2 · NCT05972564
- genisteinPhase 1/2 · NCT07033767
- GUB-UCN2Phase 1/2 · NCT07702890
- HS235Phase 1/2 · NCT07123779
- Iohexol Inj 300 MG/MLPhase 1/2 · NCT03584217
- Laser acupuncturePhase 1/2 · NCT06703788
- Liver-expressed antimicrobial peptide 2Phase 1/2 · NCT07897383
- MoxonidinePhase 1/2 · NCT05312892
- Naltrexone hydrochloridePhase 1/2 · NCT07398404 · NCT07224087
- Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)Phase 1/2 · NCT06239116
- Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Phase 1/2 · NCT06239116
- Part C: RM-718Phase 1/2 · NCT06239116
- Part D: RM-718Phase 1/2 · NCT06239116
- Renal BiopsyPhase 1/2 · NCT03584217
- RN3161Phase 1/2 · NCT07245771
- SalinePhase 1/2 · NCT02646475 · NCT04715022 · NCT06482853 · NCT07230496
- SRSD384 injectionPhase 1/2 · NCT07557355
- Vaginal SeedingPhase 1/2 · NCT03298334
- WVE-007Phase 1/2 · NCT06842186
- Yogurt smoothiePhase 1/2 · NCT03418857
- Yogurt smoothie with BB-12Phase 1/2 · NCT03418857
- [1-13C] sodium acetatePhase 1 · NCT06354088
- [11C]raclopridePhase 1 · NCT07915986
- [6,6-2H2] D-glucosePhase 1 · NCT06354088
- 102 placebo + salinePhase 1 · NCT07230496
- 20% D-glucose (aq)Phase 1 · NCT06558422
- AcetaminophenPhase 1 · NCT07738614 · NCT07525791 · NCT07803744 · NCT07502001 · NCT07710729 · NCT07508241
- Acetaminophen (APAP)Phase 1 · NCT07013643
- ACI-19764 at dose A1Phase 1 · NCT07463196
- ACI-19764 at dose A2Phase 1 · NCT07463196
- ACI-19764 at dose A3Phase 1 · NCT07463196
- ACI-19764 at dose A4Phase 1 · NCT07463196
- ACI-19764 at dose A5Phase 1 · NCT07463196
- ACI-19764 at dose A6Phase 1 · NCT07463196
- ACI-19764 at dose B1Phase 1 · NCT07463196
- ACI-19764 at dose B2Phase 1 · NCT07463196
- ACI-19764 at dose B3Phase 1 · NCT07463196
- ACI-19764 at dose C1Phase 1 · NCT07463196
- ActosPhase 1 · NCT06446531
- AcyclovirPhase 1 · NCT05589688
- ALN-6222Phase 1 · NCT07624071
- Alpelisib 300 mgPhase 1 · NCT06354088 · NCT07778524
- Angiotensin-(1-7)Phase 1 · NCT02646475 · NCT06482853
- ASC35 Injection B, for subcutaneous usePhase 1 · NCT07842640
- ASC35 Placebo Injection B, for subcutaneous usePhase 1 · NCT07842640
- ASC36 Injection A, for subcutaneous usePhase 1 · NCT07893093
- ASC36 Injection B, for subcutaneous usePhase 1 · NCT07893093
- ASC36 Placebo Injection A, for subcutaneous usePhase 1 · NCT07893093
- ASC36 Placebo Injection B, for subcutaneous usePhase 1 · NCT07893093
- ASC36 placebo tabletsPhase 1 · NCT07893106
- ASC36 tablets, for oral usePhase 1 · NCT07893106
- AtezolizumabPhase 1 · NCT05542407
- AtorvastatinPhase 1 · NCT07502001 · NCT07534592
- Atorvastatin calciumPhase 1 · NCT07785934
- atorvastatin calcium tabletPhase 1 · NCT07362030
- AZD1043Phase 1 · NCT07511205
- AZD6234 solution for injectionPhase 1 · NCT07911514
- AZD9550 solution for injectionPhase 1 · NCT07911514
- BGM1812Phase 1 · NCT07224399
- BI 456906Phase 1 · NCT05202353
- BLX-0871Phase 1 · NCT07140081
- BLX-7006Phase 1 · NCT07140055
- BrenipatidePhase 1 · NCT07476118
- Bupropion HCl Extended ReleasePhase 1 · NCT07224087
- Cagrilintide B and placebo semaglutide IPhase 1 · NCT07597018
- Cagrilintide DPhase 1 · NCT07597018
- CagriSema (Cagrilintide B + semaglutide I)Phase 1 · NCT07184086
- CG-0416Phase 1 · NCT07724431
- Clonidine PillPhase 1 · NCT04934228
- CMS-D008Phase 1 · NCT07518589
- COCPhase 1 · NCT07523711
- Cocktail (Warfarin/Caffeine/Midazolam)Phase 1 · NCT07710768
- Combined oral contraceptivePhase 1 · NCT07808060
- CX11Phase 1 · NCT07652047
- DA-1726Phase 1 · NCT06252220
- Deuterated water (2H2O/D2O), 70%Phase 1 · NCT07403604
- Diazoxide Oral Suspension, 2 mg per kg per dosePhase 1 · NCT07403604
- DigoxinPhase 1 · NCT07785934 · NCT07502001
- Digoxin TabletsPhase 1 · NCT07362030
- Drug Metabolizing EnzymePhase 1 · NCT05822544
- DWC202502Phase 1 · NCT07539415
- DWC202503Phase 1 · NCT07539415
- DWRX5003Phase 1 · NCT07539415
- Efsubaglutide Alfa 10 mg QWPhase 1 · NCT07693426
- Efsubaglutide Alfa 5 mg QWPhase 1 · NCT07693426
- Efsubaglutide Alfa placeboPhase 1 · NCT07693426
- Elecoglipron Reference Formulation Dose APhase 1 · NCT07723833
- Elecoglipron Reference Formulation Dose BPhase 1 · NCT07723833
- Elecoglipron Test formulation 1 Dose APhase 1 · NCT07723833
- Elecoglipron Test formulation 1 Dose BPhase 1 · NCT07723833
- Elecoglipron Test formulation 2 Dose APhase 1 · NCT07723833
- Elecoglipron Test formulation 2 Dose BPhase 1 · NCT07723833
- Ethinyl estradiol/Levonorgestrel (EE/LEVO)Phase 1 · NCT07013643
- Follicle Stimulating HormonePhase 1 · NCT06414096
- Formulation 1 solution for injectionPhase 1 · NCT07911514
- Formulation 2 solution for injectionPhase 1 · NCT07911514
- Formulation 3 solution for injectionPhase 1 · NCT07911514
- Formulation 4 solution for injectionPhase 1 · NCT07911514
- Formulation APhase 1 · NCT07407348
- Formulation B6Phase 1 · NCT07407348
- GlucagonPhase 1 · NCT06558422 · NCT02817659 · NCT03139305
- Glucose-dependent Insulinotropic Polypeptide (GIP)Phase 1 · NCT07411560
- Growth Hormone, HumanPhase 1 · NCT06558422
- GZC8072 TabletsPhase 1 · NCT07784699
- GZR18 injection APhase 1 · NCT07355738
- GZR18 injection BPhase 1 · NCT07355738
- GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsPhase 1 · NCT07128888
- Harvard Apparatus PHD ULTRA CP syringe pumpPhase 1 · NCT06558422
- HDM1002Phase 1 · NCT07331389
- HDM1005 injectionPhase 1 · NCT07502001
- HEC-007 injectionPhase 1 · NCT07102251
- HM17321Phase 1 · NCT07219589
- HRS-4729Phase 1 · NCT07807059
- HRS-5817 InjectionPhase 1 · NCT06934408
- HRS-5817 Injection PlaceboPhase 1 · NCT06934408
- HRS-9531 TabletPhase 1 · NCT07150962
- HRS9531 injection；PlaceboPhase 1 · NCT07559136
- HS-20094 AI pen;Phase 1 · NCT07057674
- HS-20094 MDV penPhase 1 · NCT07057674
- HS-20136-2Phase 1 · NCT07716241
- HUC2-676Phase 1 · NCT07337174
- HUC2-676-RPhase 1 · NCT07337174
- Hydrochlorothiazide 12.5Mg TabPhase 1 · NCT04934228
- Hyperinsulinemic-euglycemic clampPhase 1 · NCT06105931
- IBI3032Phase 1 · NCT07170319
- IBI3042Phase 1 · NCT07793019 · NCT07802899
- IBI3046Phase 1 · NCT07809945
- IBIO-600Phase 1 · NCT07487376
- IBIO-610Phase 1 · NCT07890870
- Injectable semaglutide or injectable tirzepatidePhase 1 · NCT06575738
- Insulin humanPhase 1 · NCT06558422
- Intravenous immune globulin GPhase 1 · NCT05584631
- INV-347Phase 1 · NCT07153172
- Jardiance 25Mg TabletPhase 1 · NCT06446531
- KN069Phase 1 · NCT06547775
- LAE102 injection in combined with LAE103 injectionPhase 1 · NCT07230496
- LAE102 intravenous administrationPhase 1 · NCT06493084
- LAE102 multiple subcutaneous administrationPhase 1 · NCT06493084
- LAE102 subcutaneous administrationPhase 1 · NCT06493084
- LAE103 injectionPhase 1 · NCT07230496
- LY3537031Phase 1 · NCT06606106
- LY4167586Phase 1 · NCT07881887 · NCT07225556
- LY4174794Phase 1 · NCT07654972
- LY4247147Phase 1 · NCT07915245
- LY4329090Phase 1 · NCT07808073
- MAD: subcutaneous injection in the abdomenPhase 1 · NCT07765160
- MBX 4291Phase 1 · NCT07142707
- Metformin hydrochloridePhase 1 · NCT07785934
- Metformin TabletsPhase 1 · NCT07362030
- MidazolamPhase 1 · NCT07331389
- MK-4082 Formulation 1 (F1)Phase 1 · NCT07748351
- MK-4082 Formulation 2 (F2)Phase 1 · NCT07748351
- MK-4082 Formulation 4 (F4)Phase 1 · NCT07748351
- MWN105 1Phase 1 · NCT07803809
- MWN105 2Phase 1 · NCT07803809
- MWN105 3Phase 1 · NCT07803809
- MWN109 tabletPhase 1 · NCT06938269
- MWN110Phase 1 · NCT07779980
- MWN117Phase 1 · NCT07824804
- NeuroEXPLORERPhase 1 · NCT07915986
- NNC0113-5840Phase 1 · NCT07566390
- NNC0497-0040Phase 1 · NCT07578584
- NNC0638-0355Phase 1 · NCT06577766
- NNC0721-8060Phase 1 · NCT07767175
- NNC6022-0004Phase 1 · NCT07693868
- NNC6989-0001Phase 1 · NCT07437079
- Octreotide AcetatePhase 1 · NCT06558422
- ONC201Phase 1 · NCT05542407
- Oral contraceptivePhase 1 · NCT07525791 · NCT07710729
- Oral SemaglutidePhase 1 · NCT07225816
- ParacetamolPhase 1 · NCT07845578
- PF-08642534Phase 1 · NCT07731139
- PF-08656795Phase 1 · NCT07876518
- PhentolaminePhase 1 · NCT03318094
- PitavastatinPhase 1 · NCT06982131
- REGN20934Phase 1 · NCT07594093
- RO7795081Phase 1 · NCT06982131 · NCT07499050
- RosuvastatinPhase 1 · NCT06982131 · NCT07534592
- RT-114 is the RaniPill capsule with PG-102 for the treatment of obesityPhase 1 · NCT06891287
- Rybelsus TabletPhase 1 · NCT06446531
- SA030 InjectionPhase 1 · NCT07479862
- SAD: subcutaneous injection in the abdomenPhase 1 · NCT07765160
- SC VK3019Phase 1 · NCT07846033
- SCB0020160Phase 1 · NCT07682337
- Semaglutide 1.0 mgPhase 1 · NCT07772960
- Semaglutide 2.0 mgPhase 1 · NCT07772960
- Semaglutide Implant (NPM-139)Phase 1 · NCT07430059
- Semaglutide Nasal SprayPhase 1 · NCT07465965
- Semaglutide Pen Injector [Ozempic]Phase 1 · NCT05071898
- semaglutide SCPhase 1 · NCT07673900
- SGB-7342Phase 1 · NCT07324850
- SGB-7342-Matching placeboPhase 1 · NCT07324850
- SHR-1179 ; PlaceboPhase 1 · NCT07826364
- SHR-2906 InjectionPhase 1 · NCT07280936
- SHR-2906 Injection PlaceboPhase 1 · NCT07280936
- Sodium NitroprussidePhase 1 · NCT03318094
- Subcutaneous immune globulin GPhase 1 · NCT05584631
- Subcutaneous single and mutiple dosePhase 1 · NCT06859853
- SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)Phase 1 · NCT07905560
- SUN-0864 or placeboPhase 1 · NCT07905560
- Survodutide formulation APhase 1 · NCT07768813
- Survodutide formulation B2Phase 1 · NCT07768813
- SYH2082 InjectionPhase 1 · NCT07532655 · NCT07736404
- SYH2092 InjectionPhase 1 · NCT07776041
- SYH9017Phase 1 · NCT06830343
- TIX100Phase 1 · NCT07675590
- TLC-6740 Oral SolutionPhase 1 · NCT05822544
- TLC-6740 TabletPhase 1 · NCT05822544
- TQF3250 capsulesPhase 1 · NCT07798284 · NCT07747857
- TQF3250 placeboPhase 1 · NCT07798284 · NCT07747857
- TQF6422 InjectionPhase 1 · NCT07794111
- TQF6422 PlaceboPhase 1 · NCT07794111
- UBT37034Phase 1 · NCT07873645
- VK2735 DrugPhase 1 · NCT07838740
- VRB-101Phase 1 · NCT07628127
- VRB-103Phase 1 · NCT07628127
- VX-201Phase 1 · NCT07673900
- WarfarinPhase 1 · NCT07331389 · NCT07502001
- Warfarin SodiumPhase 1 · NCT07785934
- Warfarin Sodium TabletsPhase 1 · NCT07362030
- XTL6001Phase 1 · NCT07205432
- Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate AnalyzerPhase 1 · NCT06558422
- Zenagamtide injectionPhase 1 · NCT07815067
- Zenagamtide tabletPhase 1 · NCT07815067
- ZovaglutidePhase 1 · NCT07443059 · NCT07916194
- ZT002 injectionPhase 1 · NCT07697846
- ZT002 injection matching placeboPhase 1 · NCT07697846
- ZT002 injection, metformin, warfarinPhase 1 · NCT07550816
- ZT002 injection, rosuvastatin, digoxinPhase 1 · NCT07550816
- ZT003 - Part 2(Multiple ascending dose )Phase 1 · NCT07184502
- ZT003 - Part1 (Single ascending dose )Phase 1 · NCT07184502
- Apple Cider VinegarEarly phase 1 · NCT05802121
- cold waterEarly phase 1 · NCT07261475
- Crocus sativus tepals cold aqueous extractEarly phase 1 · NCT07261475
- EpinephrineEarly phase 1 · NCT06416969
- Glucagon-like peptide-1 receptor agonists (GLP 1 RA)Early phase 1 · NCT06807970
- HRS-5817Early phase 1 · NCT07238647
- human insulinEarly phase 1 · NCT07874945 · NCT07653464
- Inhalation - Natural OdourEarly phase 1 · NCT06370845
- Inhalation - PlaceboEarly phase 1 · NCT06370845
- InsulinEarly phase 1 · NCT06392854
- IsoproterenolEarly phase 1 · NCT05219799
- Milk Polar Lipid-Rich Dairy PowderEarly phase 1 · NCT05700916
- MisoprostolEarly phase 1 · NCT06199154
- MounjaroEarly phase 1 · NCT06734273
- Neuropeptide YEarly phase 1 · NCT04838678
- NorepinephrineEarly phase 1 · NCT05219799
- Phentermine/Topiramate (Qsymia)Early phase 1 · NCT04881799
- Phentolamine MesylateEarly phase 1 · NCT05219799
- PioglitazoneEarly phase 1 · NCT03866408
- Propranolol HydrochlorideEarly phase 1 · NCT05219799
- Qingxin Jiaotai DecoctionEarly phase 1 · NCT07754383
- Sleeve GastrectomyEarly phase 1 · NCT06734273
- SomatostatinEarly phase 1 · NCT06416969
- Standard Oral Hypoglycemic AgentEarly phase 1 · NCT07209527
- Team-based shared decision-makingEarly phase 1 · NCT07662616
- Truway Blood Glucose MonitorEarly phase 1 · NCT07209527
- Truway Portable Ultrasound DeviceEarly phase 1 · NCT07209527
- ZP6590, solution for injectionEarly phase 1 · NCT07721597
Closest to patients
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesitySCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityHospital CUF Porto S.A. · Porto, Portugal + 27 more hospitalsPhase 3Primary completion 2023
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightA Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightHealth Step Finland Oy · Kuopio, Finland + 233 more hospitalsPhase 3Primary completion 2024
- A Trial of Setmelanotide in Acquired Hypothalamic ObesityA Trial of Setmelanotide in Acquired Hypothalamic ObesityBoston Children's Hospital · Boston, United States + 27 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Incretin-Based Therapies in Prostate Cancer: From Metabolic Protection to Potential Antitumour Activity - A Narrative Review.
Incretin-Based Therapies in Prostate Cancer: From Metabolic Protection to Potential Antitumour Activity - A Narrative Review.
Endocrine-related cancer
PubMed · PMID 42980483Publication
Oleanolic Acid and Ursolic Acid Alleviate Obesity-Induced Skeletal Muscle Atrophy via Activation of the IRS/PI3K/AKT/mTOR Signaling Pathway and Attenuation of Oxidative Stress.
Oleanolic Acid and Ursolic Acid Alleviate Obesity-Induced Skeletal Muscle Atrophy via Activation of the IRS/PI3K/AKT/mTOR Signaling Pathway and Attenuation of Oxidative Stress.
Journal of agricultural and food chemistry
PubMed · PMID 42980440Randomised trial
A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial.
A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PubMed · PMID 42980655Review
Diabesity: an old term, a modern challenge - multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes.
Diabesity: an old term, a modern challenge - multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
PubMed · PMID 42978695Review
Type 2 diabetes and the cardio-renal-metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists.
Type 2 diabetes and the cardio-renal-metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists.
TouchREVIEWS in endocrinology
PubMed · PMID 42979257
Organisations that can help
Helplines, patient groups and support services for you and your family.
International & European
European Coalition for People living with Obesity
Patient-led European coalition of national obesity patient groups: campaigns (People First language, #LivingWithObesity), patient lounge, podcasts, family resources, advocacy.
Visit site: European Coalition for People living with ObesityEuropean Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)Global Obesity Patient Alliance
Global coalition of obesity patient organisations giving people living with obesity a unified voice in advocacy.
Visit site: Global Obesity Patient AllianceInternational Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' OrganizationsWorld Obesity Federation
Professional body (mixed): federation of national/regional obesity associations, some representing people with lived experience; World Obesity Day, policy, patient portal.
Visit site: World Obesity Federation
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Obesity work.
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Instituto de Salud Carlos III
Madrid, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of North Carolina at Chapel Hill
Chapel Hill, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Universidade de São Paulo
São Paulo, Brazil
Team details appear once the team leader joins.
Is this your team? Claim it
Imperial College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it